Ultragenyx Pharmaceutical (RARE) Equity Average (2014 - 2026)

Ultragenyx Pharmaceutical (RARE) has 13 years of Equity Average data on file, last reported at -$158.0 million in Q1 2026.

• Equity Average for Q1 2026 came in at -$158.0 million, down 179.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$158.0 million (down 179.2% YoY), and the FY2025 annual result was $87.5 million, down 66.98% from the prior year.
• Equity Average declined to -$158.0 million in Q1 2026 per RARE's latest filing, from -$35.4 million in the prior quarter.
• Over five years, Equity Average peaked at $859.5 million in Q1 2022 and troughed at -$158.0 million in Q1 2026.
• A 5-year average of $276.1 million and a median of $207.6 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2026: Equity Average jumped 384.77% in 2024, then plunged 179.2% in 2026.
• A 5-year view of Equity Average shows it stood at $410.4 million in 2022, then slumped by 62.63% to $153.4 million in 2023, then jumped by 96.22% to $300.9 million in 2024, then tumbled by 111.77% to -$35.4 million in 2025, then sank by 346.07% to -$158.0 million in 2026.
• Business Quant data shows RARE's Equity Average at -$158.0 million in Q1 2026, -$35.4 million in Q4 2025, and $80.2 million in Q3 2025.